Although Caenorhabditis elegans has been utilized extensively to study synapse formation and function, relatively little is known about synaptic plasticity in C. elegans. We show that a brief treatment with the cholinesterase inhibitor aldicarb induces a form of presynaptic potentiation whereby ACh release at neuromuscular junctions (NMJs) is doubled. Aldicarb-induced potentiation was eliminated by mutations that block processing of proneuropeptides, by mutations inactivating a single proneuropeptide (NLP-12), and by those inactivating an NLP-12 receptor (CKR-2). NLP-12 expression is limited to a single stretch-activated neuron, DVA. Analysis of a YFP-tagged NLP-12 suggests that aldicarb stimulates DVA secretion of NLP-12. Mutations disrupting the DVA mechanoreceptor (TRP-4) decreased aldicarb-induced NLP-12 secretion and blocked aldicarb-induced synaptic potentiation. Mutants lacking NLP-12 or CKR-2 have decreased locomotion rates. Collectively, these results suggest that NLP-12 mediates a mechanosensory feedback loop that couples muscle contraction to changes in presynaptic release, thereby providing a mechanism for proprioceptive control of locomotion.
INTRODUCTION
Neuropeptides represent a vast and chemically diverse set of neurotransmitters. Proneuropeptides are packaged into large dense core vesicle (DCV) precursors, where they are processed into active forms by copackaged enzymes. Many, and perhaps all, neurons express and secrete neuropeptides. Expression of specific neuropeptides is often utilized as a marker to distinguish subclasses of neurons. For example, subclasses of mouse cortical interneurons are distinguished by their expression of cholecystokinin and somatostatin (Kawaguchi and Kondo, 2002) . Despite their widespread expression, relatively little is known about how specific neuropeptides function within circuits.
Secretion of neuromodulatory peptides has often been proposed as a mechanism for regulating synaptic efficacy and producing adaptive changes in behavior; however, genetic studies of neuropeptide function have primarily focused on endocrine functions. In a few cases, the impact of specific neuropeptides has been explored in particular circuits. For example, specific neuropeptides have been implicated in adaptation of odorant responses (Chalasani et al., 2010; Ignell et al., 2009) , in ethanol sensitivity (Davies et al., 2004; Moore et al., 1998) , and in regulation of circadian behaviors (Lear et al., 2005; Mertens et al., 2005; Renn et al., 1999) . Much remains to be learned about how neuropeptides shape the function of these and other behavioral circuits.
The nematode C. elegans has been utilized as a genetic model to study neuropeptide function. The genome sequence predicts 115 proneuropeptide genes, encoding 250 different mature peptides (Li and Kim, 2008) . Many of these predicted peptides have been confirmed by mass spectrometry (Husson et al., 2006 . Mutations have been described that disrupt proneuropeptide processing (egl-3 PC2, egl-21 CPE, and sbt-1 7B2), maturation of DCVs , and exocytosis of DCVs (unc-31 CAPS and pkc-1 PKC3) (Edwards et al., 2009; Jacob and Kaplan, 2003; Kass et al., 2001; Sieburth et al., 2005 Sieburth et al., , 2007 Speese et al., 2007; Sumakovic et al., 2009 ). Hereafter, we refer to these mutants collectively as neuropeptide-deficient mutants.
Several prior studies suggested that neuropeptides regulate transmission at cholinergic NMJs in C. elegans. Sensitivity of C. elegans to paralysis induced by the cholinesterase inhibitor aldicarb has been used as a measure of acetylcholine release (ACh) at neuromuscular junctions (Miller et al., 1996) . Mutations that decrease ACh secretion confer resistance to aldicarbinduced paralysis Saifee et al., 1998) , while those that increase ACh secretion cause aldicarb hypersensitivity (Gracheva et al., 2006; McEwen et al., 2006; Vashlishan et al., 2008) . Many neuropeptide-deficient mutants are aldicarb resistant, implying that endogenous neuropeptides regulate synaptic transmission (Edwards et al., 2009; Jacob and Kaplan, 2003; Kass et al., 2001; Sieburth et al., 2005 Sieburth et al., , 2007 Speese et al., 2007; Sumakovic et al., 2009) ; however, the synaptic basis for the aldicarb resistance of neuropeptide mutants has not been determined. Electrophysiological recordings have been reported for four neuropeptidedeficient mutants. In three cases , baseline transmission was unaltered whereas in the fourth case (unc-31 CAPS) transmission was modestly reduced (Edwards et al., 2009; Gracheva et al., 2007; Sieburth et al., 2007; Sumakovic et al., 2009 ). This discrepancy may reflect the fact that CAPS has also been proposed to directly promote SV exocytosis (Jockusch et al., 2007) . Thus, it remains unclear how neuropeptides alter neuromuscular signaling.
Here we show that aldicarb treatment potentiates ACh release in wild-type animals, that the neuropeptide NLP-12 is required for this effect, and that NLP-12 is secreted by a stretch-activated mechanosensory neuron (DVA). Collectively, our results suggest that NLP-12 provides proprioceptive feedback that couples muscle contraction to changes in presynaptic release. These results provide a synaptic mechanism for proprioceptive control of locomotion behavior.
RESULTS
Mutants Lacking egl-3 PC2 Have Wild-Type Baseline Synaptic Transmission To further address the impact of endogenous neuropeptides on cholinergic transmission, we recorded excitatory postsynaptic currents (EPSCs) from adult body muscles of egl-3 PC2 mutants (Figure 1 ). The egl-3 gene encodes a protease that is most similar to proprotein convertase type 2 (PC2) (Kass et al., 2001 ) and egl-3 PC2 mutants have severe defects in proneuropeptide processing (Husson et al., 2006; Jacob and Kaplan, 2003) . Like other neuropeptide-deficient mutants, egl-3 mutants were resistant to aldicarb-induced paralysis ( Figure 1I ) (Jacob and Kaplan, 2003) . We recorded both endogenous EPSCs, which are Figures 1, 2, 3 , and 5. All comparisons to this control data set were corrected for multiple comparisons using the Tukey-Kramer test. All electrophysiological data are shown in Table S1 .
Neuron
A Neuropeptide Mechanosensory Feedback Loop synaptic events mediated by the endogenous activity of cholinergic motor neurons, as well as EPSCs evoked by a depolarizing stimulus. In egl-3 null mutants, the rate, amplitude, and kinetics of endogenous EPSCs, and the amplitude and total synaptic charge of evoked EPSCs were all unaltered compared to wildtype controls (Figure 1 ; see Figure S1 and Table S1 available online). These results are consistent with prior studies of several other neuropeptide-defective mutants (e.g., pkc-1 PKC3, unc-108 Rab2, and ric-19 ICA69) (Edwards et al., 2009; Sieburth et al., 2007; Sumakovic et al., 2009) . Aldicarb resistance can also arise from increased transmission at GABAergic NMJs (Mullen et al., 2006) , which could potentially explain the phenotype of neuropeptide mutants. To test this possibility, we recorded inhibitory postsynaptic currents (IPSCs) from adult body muscles. The rate and amplitude of endogenous IPSCs observed in egl-3 PC2 mutants were indistinguishable from those observed in wild-type controls (Figures S1A-S1C). Collectively, these results suggest that changes in baseline transmission at cholinergic or GABAergic NMJs cannot account for the aldicarb resistance of neuropeptide mutants.
Aldicarb Treatment Potentiates Cholinergic Transmission
Aldicarb sensitivity is assayed by measuring the onset of paralysis during a 2 hr aldicarb treatment. Given the prolonged time course of these assays, we reasoned that aldicarb exposure might alter synaptic transmission, which could account for the discrepancy between the behavioral and electrophysiological phenotypes of the neuropeptide mutants. To test this idea, we recorded body muscle EPSCs after a 60 min pretreatment with aldicarb. Aldicarb treatment significantly increased the rate of endogenous EPSCs, and the total synaptic charge of evoked EPSCs, both indicating enhanced cholinergic transmission (Figures 1A-1F ; Table S1 ). By contrast, aldicarb treatment did not alter the IPSC rate of either wild-type or egl-3 mutants, suggesting that this effect was specific for cholinergic transmission (Figures S1A and S1B).
The synaptic potentiation following aldicarb treatment could be caused by either a pre-or postsynaptic change. The increased rate of endogenous EPSCs suggests a presynaptic origin for the potentiation. Nonetheless, we did several additional experiments to rule out postsynaptic changes. First, aldicarb treatment did not alter the amplitude or kinetics of endogenous EPSCs ( Figure 1C ; Figures S1D-S1G, and Table S1), both suggesting that muscle sensitivity to synaptically released ACh was unaltered. Second, aldicarb treatment did not increase the amplitude of currents activated by application of exogenous ACh (Figures 1G and 1H ; Table S1 ). In fact, ACh-activated currents were significantly decreased by aldicarb treatment. Third, aldicarb treatment did not increase the abundance of GFP-tagged ACR-16 nicotinic receptors in body muscles (K.B., unpublished data). Therefore, aldicarb-induced synaptic potentiation was more likely caused by a presynaptic change in ACh release.
NLP-12 Is Required for Aldicarb-Induced Synaptic Potentiation
The resistance of neuropeptide-deficient mutants to aldicarbinduced paralysis could be caused by defects in aldicarbinduced synaptic potentiation. Consistent with this idea, the aldicarb-induced increase in EPSC rate and in evoked synaptic charge were both eliminated in egl-3 PC2 mutants (Figures 1B  and 1F ; Table S1 ). This lack of aldicarb-induced potentiation was not caused by a generalized defect in synaptic transmission because endogenous and evoked EPSCs observed in untreated egl-3 PC2 mutants were indistinguishable from wild-type controls (Figure 1 ; Figure S1 and Table S1 ).
In a large RNAi screen, we found that inactivation of several proneuropeptide encoding genes (including ins-22, ins-31, flp-1, and nlp-12) causes resistance to aldicarb-induced paralysis (Sieburth et al., 2005) . Aldicarb resistance phenotypes were confirmed for flp-1 and nlp-12 using available knockout alleles (Sieburth et al., 2005) . The aldicarb resistance of nlp-12 mutants was much stronger than that of flp-1 mutants; consequently, we focused our subsequent analysis on nlp-12.
If an nlp-12-encoded neuropeptide mediates aldicarbinduced paralysis and synaptic potentiation, then nlp-12 and egl-3 mutations should have very similar effects on behavior and synaptic transmission. Several results support this idea. First, nlp-12 and egl-3 mutations did not have additive effects on aldicarb-induced paralysis, consistent with their functioning together in this process ( Figure 2C ). Second, baseline endogenous and evoked EPSCs were unaltered in nlp-12 single mutants ( Figure 2 ; Figure S2 and Table S2 ), as was the case in egl-3 PC2 mutants ( Figure 1 ; Figure S1 and Table S1 ). Third, the aldicarbinduced increases in EPSC rate and evoked synaptic charge were both eliminated in nlp-12 mutants and were restored by a transgene containing an nlp-12 genomic clone ( Figure 2 ). Collectively, these results support the idea that an nlp-12-encoded peptide is required for the behavioral and synaptic effects of aldicarb.
An NLP-12 Receptor, CKR-2, Is Also Required for Aldicarb-Induced Potentiation The ckr-2 gene encodes a G protein-coupled receptor that is most similar to mammalian gastrin receptors (Janssen et al., 2008) . NLP-12 peptides are high affinity agonists for CKR-2 receptors expressed in tissue culture cells (Janssen et al., 2008) . Prompted by these results, we tested ckr-2 mutants for defects in aldicarb-induced paralysis and synaptic potentiation. Like nlp-12 mutants, ckr-2 mutants were resistant to aldicarbinduced paralysis, had normal baseline cholinergic transmission, but lacked aldicarb-induced increases in EPSC rate and evoked synaptic charge (Figure 3 ; Figure S3 and Table S3 ). The nlp-12 and ckr-2 mutations did not have additive effects on aldicarbinduced paralysis nor on baseline synaptic transmission (Figure 3C ; Table S3 ). A transcriptional reporter containing the ckr-2 promoter was expressed in both cholinergic and GABAergic motor neurons ( Figure 3F ). The behavioral and electrophysiological defects of ckr-2 mutants were rescued by transgenes expressing CKR-2 in all cholinergic neurons (using the unc-17 VAChT promoter), in cholinergic motor neurons (using the acr-2 promoter), but not by those expressed in GABAergic neurons (using the unc-25 GAD promoter) ( Figure 3 ; Table S3 ). These results suggest that CKR-2 functions in cholinergic neurons, mediating the effects of aldicarb on behavior and synaptic transmission.
Thus far, our results are most consistent with the idea that NLP-12's effects on cholinergic transmission are presynaptic. In contrast, a prior study showed that NLP-12 application induces contraction of isolated A. suum muscle strips (McVeigh et al., 2006) , suggesting a direct effect on muscle. Based on these results, we did several additional experiments to determine if NLP-12 and CKR-2 have postsynaptic effects. First, we analyzed ACh-activated muscle currents, finding that the currents recorded from untreated nlp-12 and ckr-2 mutants were indistinguishable from wild-type controls (Figures S2D, S2E, S3D, and S2E and Tables S2 and S3) . Second, aldicarb treatment significantly reduced the amplitude of ACh-activated currents in wild-type muscles (Figures 1G and 1H ; Table S1 ), and identical effects were observed in aldicarb-treated nlp-12 (Figures S2D and S2E and Table S2 ) and ckr-2 (Figures S3D  and S3E and Table S3 ) mutant muscles. Third, to assess muscle responses to synaptically released ACh, we analyzed endogenous EPSCs. We found that neither the amplitude nor the kinetics of endogenous EPSCs were significantly altered in control and aldicarb treated wild-type (Figures S1D-S1G and  Table S1 ), nlp-12 (Figures S2A-S2C and Table S2 ), and ckr-2 (Figures S3A-S3C and Table S3 ) animals. Thus, changes in muscle responsiveness to ACh were not observed in nlp-12 and ckr-2 mutants. Finally, the ckr-2 transcriptional reporter was not expressed in body muscles (data not shown). Collectively, our results are most consistent with the idea that NLP-12 and CKR-2 potentiate cholinergic transmission through a presynaptic mechanism.
NLP-12 Is Expressed in DVA Neurons
We analyzed a reporter construct containing the nlp-12 promoter driving expression of GFP. This reporter construct was expressed in a single tail neuron, DVA, consistent with prior studies (Janssen et al., 2008) .
Fluorescently tagged proneuropeptides have been used to monitor secretion in C. elegans Sieburth et al., 2007) ; therefore, we reasoned that a similar approach could be utilized to analyze NLP-12 secretion. Expression of NLP-12::YFP in DVA (using the nlp-12 promoter) showed a punctate distribution in the DVA axon, in both the ventral nerve cord and in the nerve ring ( Figure 4A ). Several results suggest that the NLP-12 puncta correspond to DCVs containing NLP-12::YFP. First, expression of the NLP-12::YFP transgene rescued the nlp-12 mutant defects in aldicarb-induced paralysis ( Figure 2C ) and synaptic potentiation (data not shown), demonstrating that the tagged proneuropeptide retains biological activity. Second, NLP-12 puncta fluorescence was significantly increased in unc-13 Munc13 mutants (which are defective for DCV secretion) (Sieburth et al., 2007; Speese et al., 2007) (Figures 4A and 4B; Figures S4C and S4D) . Taken together, these results indicate that DVA neurons express and actively secrete NLP-12. Table S2 .
Neuron
A Neuropeptide Mechanosensory Feedback Loop NLP-12::YFP behaved differently from other neuropeptide constructs that we previously analyzed. For other neuropeptides (e.g., NLP-21::YFP expressed in DA motor neurons), YFP secreted by neurons is taken up by specialized phagocytic cells in the body cavity (termed coelomocytes), where it can be quantified as a fluorescent signal (Sieburth et al., 2007) . For NLP-12::YFP, we were unable to detect coelomocyte fluorescence ( Figure S4F ). This distinction apparently results from expression of NLP-12 in the DVA neuron, which has an axon in the ventral nerve cord. When NLP-12::YFP was expressed in DA neurons, we observed fluorescent puncta in both dorsal cord axons and in coelomocytes ( Figure S4E) ; however, this transgene was unable to rescue the nlp-12 mutant defect in aldicarb-induced paralysis ( Figure 2C) . Conversely, when NLP-21::YFP was expressed in DVA, coelomocyte fluorescence was not detected (data not shown). These results suggest that YFP secreted in the ventral nerve cord cannot be internalized by coelomocytes, perhaps because it is endocytosed by another cell type (e.g., the ventral hypodermis, or body muscles) or cannot efficiently diffuse out of the ventral cord tissue.
Aldicarb Treatment Stimulates NLP-12 Secretion from DVA Neurons If NLP-12 mediates the effects of aldicarb on behavior and synaptic transmission, we would expect that aldicarb treatment would stimulate NLP-12 secretion from DVA. Consistent with this idea, we found that aldicarb treatment resulted in a rapid and significant decrease in NLP-12 puncta fluorescence in DVA axons (Figures 4A and 4B ; Figure S4A ). This effect was specific for NLP-12 secretion by DVA, as aldicarb treatment did not decrease NLP-21 puncta fluorescence in DA motor neurons ( Figures 4C and 4D ). The effect of aldicarb on NLP-12 puncta fluorescence was eliminated in both unc-31 CAPS and unc-13 Munc13 mutants ( Figure 4B ; Figures S4C and S4D) , implying that the aldicarb-induced decrease in NLP-12 puncta fluorescence was mediated by increased NLP-12 secretion. These results support the idea that aldicarb stimulates NLP-12 secretion by DVA neurons, thereby potentiating cholinergic transmission and paralysis. Consistent with this idea, a transgene driving NLP-12 expression in DA motor neurons failed to rescue the nlp-12 mutant aldicarb-induced paralysis defect (+ and -aldicarb) were utilized in Figures 1, 2, 3 , and 5. All comparisons to this control data set were corrected for multiple comparisons using the Tukey-Kramer test. All electrophysiological data are shown in Table S3 .
( Figure 2C ), suggesting that expression in DVA is critical for NLP-12's function.
TRP-4 Is Required for Aldicarb-Induced Plasticity
DVA has been previously proposed to function as a stretch receptor (Li et al., 2006) . Bending of the worm's body induces calcium transients in DVA that are eliminated in mutants lacking TRP-4, a mechanically gated ion channel (Kang et al., 2010; Li et al., 2006) . Prompted by these results, we tested the idea that aldicarb-induced muscle contraction provides a mechanical stimulus that induces NLP-12 secretion. Consistent with this idea, the aldicarb-induced decrease in NLP-12 puncta fluorescence was significantly reduced in trp-4 mutants (Figures 4A  and 4B ; Figure S4B ). This suggests that the ability of DVA to sense mechanical stimuli is required to stimulate NLP-12 secretion. If TRP-4 is required for aldicarb-induced NLP-12 secretion, then we would expect that trp-4 mutants would have behavioral and electrophysiological defects similar to those observed in nlp-12 mutants. As expected, trp-4 mutants were resistant to aldicarb-induced paralysis ( Figure 5F ). In addition, like nlp-12 mutants, trp-4 mutants lacked the aldicarb-induced increase in EPSC rate (Figures 5A and 5B) and in evoked synaptic charge ( Figures 5D and 5E ), while baseline cholinergic transmission was unaltered. Collectively, these results suggest that aldicarb-induced body muscle contractions induce NLP-12 secre- tion, which subsequently potentiates ACh secretion presynaptically.
NLP-12 Regulates Locomotion Behavior
Thus far, our results suggest that NLP-12 mediates a mechanosensory feedback loop that couples muscle contraction (induced by aldicarb treatment) to changes in presynaptic ACh release. To determine if NLP-12 signaling has an impact in the absence of aldicarb, we analyzed the locomotion behavior of nlp-12 mutants. A prior study showed that bending of the worm's body during swimming behavior induces calcium transients in DVA (Li et al., 2006) ; consequently, we would expect that NLP-12 secretion from DVA would also occur during normal locomotion behavior. To assess changes in locomotion, we measured the velocity of worm locomotion. We found that locomotion rate was significantly reduced in nlp-12 mutants and that this defect was rescued by an nlp-12 transgene ( Figures 6A and 6B) . A similar locomotion defect was also observed in ckr-2 mutants, which was rescued by a ckr-2 transgene expressed in cholinergic motor neurons (using the acr-2 promoter) ( Figures 6A and 6B) . These results suggest that NLP-12 secretion modulates locomotion, consistent with the idea that this mechanosensory feedback mechanism is engaged during locomotion behavior.
To further investigate the connection between NLP-12 secretion and locomotion rate, we analyzed NLP-12 secretion in strains that have differing locomotion rates ( Figure 6C) . This analysis shows that increased locomotion rates (in npr-1 mutants) are correlated with decreased NLP-12 puncta fluorescence, whereas slow locomotion (in mec-3 mutants) was accompanied by increased NLP-12 puncta fluorescence. Thus, changes in locomotion rate are accompanied by corresponding changes in NLP-12 secretion.
DISCUSSION
We describe a mechanosensory feedback mechanism whereby muscle contraction is coupled to changes in ACh release at NMJs. This feedback mechanism consists of a stretch sensitive Neuron A Neuropeptide Mechanosensory Feedback Loop neuron (DVA), which secretes the neuropeptide NLP-12 in response to muscle contraction. Activation of CKR-2, an NLP-12 receptor, potentiates transmission at cholinergic NMJs. This mechanosensory feedback is employed during spontaneous locomotion behavior to determine locomotion rate. These experiments define the synaptic basis for a simple proprioceptive feedback circuit.
Activity-Dependent Plasticity at C. elegans Synapses Aldicarb-induced paralysis has been extensively utilized as a screening tool to identify C. elegans genes required for synaptic transmission. Many genes identified as aldicarb resistant mutants were subsequently shown to encode essential components of the presynaptic release machinery (Sieburth et al., 2005) . Thus, it was somewhat surprising that neuropeptide-deficient mutants, which are all strongly aldicarb resistant, have unaltered baseline synaptic physiology. Our results provide an explanation for this puzzle. We show that brief aldicarb treatments induce a form of synaptic potentiation, which is abolished in the neuropeptide-deficient mutants. Several aspects of these results are significant. These results represent the first C. elegans paradigm for activity-induced synaptic potentiation, and the first study to document an electrophysiological effect of an endogenous C. elegans neuropeptide. Our results also suggest that additional genes involved in synaptic plasticity will be found among the genes identified in the prior screens for aldicarbresistant mutants.
NLP-12 Potentiates ACh Release at NMJs
Here we show that secretion of NLP-12 potentiates synaptic transmission at cholinergic NMJs, and that it does so by enhancing ACh release. Aldicarb treatment enhanced cholinergic transmission, which was manifested by an increase both in the rate of EPSCs and in the total synaptic charge evoked by a depolarizing stimulus. Both effects of aldicarb were eliminated by mutations inactivating NLP-12 and CKR-2 (an NLP-12 receptor). NLP-12 is expressed by a single neuron DVA, and aldicarb treatment induces NLP-12 secretion from these neurons. Collectively, these results support the idea that aldicarb treatment evokes NLP-12 secretion from DVA neurons, which subsequently potentiates cholinergic transmission.
Several results suggest that the NLP-12-mediated potentiation occurs by a presynaptic mechanism. First, the increase in endogenous EPSCs frequency is characteristic of a presynaptic change. Second, the amplitude and kinetics of endogenous EPSCs were not altered by aldicarb treatment, implying that muscle responses to individual synaptic quanta were unaltered. Third, ACh-activated muscle currents were not increased by aldicarb, suggesting that increased muscle sensitivity to ACh is unlikely to explain the aldicarb-induced synaptic potentiation. Figures 1, 2, 3 , and 5. All comparisons to this control data set were corrected for multiple comparisons using the Tukey-Kramer test. All electrophysiological data are shown in Table S4 .
In fact, aldicarb treatment significantly decreased ACh-activated current amplitudes, consistent with decreased muscle sensitivity to ACh. Identical decreases in ACh-activated currents were observed in aldicarb treated nlp-12 and ckr-2 mutants, suggesting that this effect was not mediated by NLP-12. Fourth, the ckr-2 mutant defects in aldicarb-induced potentiation, aldicarb-induced paralysis, and locomotion rate were all rescued by transgenes expressing CKR-2 in the presynaptic cholinergic neurons. Fifth, a ckr-2 transcriptional reporter was expressed in cholinergic motor neurons, but was not expressed in body muscles. Collectively, these results all support the idea that increased ACh release accounts for NLP-12-mediated potentiation of synaptic transmission.
Role of DVA as a Mechanosensory Neuron
A prior study showed that DVA neurons are stretch sensitive (Li et al., 2006) . Stretch sensitivity of DVA was documented by observing calcium transients in DVA that are phasically activated by body bends during swimming behavior (Li et al., 2006) . These swimming-induced DVA calcium transients were eliminated in mutants lacking TRP-4, a mechanoreceptor (Kang et al., 2010; Li et al., 2006) .
Our results suggest that muscle contraction provides a mechanical stimulus that induces DVA secretion of NLP-12. NLP-12 is expressed only in DVA neurons, and it has a punctate distribution in DVA axons, consistent with its packaging into dense core vesicles (DCVs). Aldicarb treatment induces body muscle contraction, which is accompanied by decreased NLP-12 fluorescence in DVA axons. This aldicarb-induced decrease of NLP-12 fluorescence is blocked by unc-31 CAPS and unc-13 Munc13 mutations (which prevent DCV exocytosis) and is diminished by trp-4 mutations (which eliminate the mechanosensitivity of DVA). By contrast, aldicarb had little effect on secretion of neuropeptides expressed by the DA motor neurons, implying that the effects of aldicarb on secretion are specific to neuropeptides expressed by the DVA neurons. Collectively, these results strongly support the idea that muscle contraction provides a mechanical stimulus that evokes increased NLP-12 secretion from DVA. Electron microscopic analysis of the ventral nerve cord also supports this idea. In the serial section reconstruction of the nervous system, the DVA axon typically lies in a dorsal position in the ventral nerve cord, adjacent to both a muscle cell membrane, and to axons of cholinergic motor neurons (typically VB neurons) ( Figure S5 ) (White et al., 1986) (www.wormimage.org). Thus, the DVA axon is well positioned for its function as a sensor of body muscle contraction, and for transducing this signal into altered cholinergic transmission.
Mechanosensory Control of Locomotion
In addition to its mechanosensory properties, DVA neurons were proposed to regulate specific aspects of worm locomotion, including the extent and speed of body bends during locomotion (Li et al., 2006) . Based on these observations, it was proposed that DVA neurons act as stretch receptors, and perhaps function in a manner analogous to proprioceptive neurons. However, the synaptic basis for DVA-mediated regulation of locomotion had not been described.
Our results provide a potential mechanism for DVA-mediated regulation of locomotion rate. In particular, we propose that body bends occurring during locomotion promote NLP-12 secretion from DVA neurons, thereby enhancing ACh release at NMJs. Consistent with this idea, the locomotion rate of nlp-12 and ckr-2 mutants was significantly reduced compared to wild-type controls. This locomotion defect provides support for the idea that NLP-12 secretion occurs during normal locomotion behavior, and that NLP-12 signaling is employed to 
Neuron
A Neuropeptide Mechanosensory Feedback Loop modulate the pattern of locomotion. We propose that NLP-12 is utilized as an internal measure of recent locomotory activity. In particular, during periods of elevated locomotion rates (e.g., during local search for food), increased body movements lead to a net increase in NLP-12 secretion which would promote the continued high rate of locomotion through enhanced ACh release. A similar model was previously proposed for DVA function, based on the locomotion defects caused by laser killing DVA neurons (Wicks and Rankin, 1995) . In these experiments, killing DVA neurons resulted in decreased forward and reverse locomotion responses to a mechanical stimulus. Based on these results, these authors proposed that DVA provides a gain control that amplifies the locomotory response of animals to mechanical stimuli (Wicks et al., 1996) . Our results provide a potential synaptic mechanism for these behavioral effects.
ckr-2 Rescue A CKR-2a cDNA clone (Janssen et al., 2008) was kindly provided by Liliane Schoofs. The cDNA was ligated into expression vectors (pPD49.26) containing the unc-17 promoter (for cholinergic rescue), the acr-2 promoter (for cholinergic motor neuron rescue), or the unc-25 promoter (for GABAergic rescue). ckr-2 Transcriptional Reporter An 8.5 kb fragment of ckr-2 genomic region, from 3008 bp upstream of the start codon to 20 bp into the second exon, was fused to a GFP containing four nuclear localization signals.
Transgenes and Germline Transformation
Transgenic strains were isolated by microinjection of various plasmids using either Pmyo-2::NLS-GFP (KP#1106) or Pmyo-2::NLS-mCherry (KP#1480) as coinjection markers. Integrated transgenes were obtained by UV irradiation of strains carrying extrachromosomal arrays. All integrated transgenes were outcrossed at least six times.
Locomotion and Behavior Assays
For aldicarb paralysis, between 18 and 25 young adult worms were transferred to plates containing 1.5 mM aldicarb and assayed for paralysis as described previously (Nurrish et al., 1999) . Worm tracking and analysis were preformed similar to previous studies (Dittman and Kaplan, 2008) with minor modifications. Briefly, worms were reared at 20 C and moved to room temperature 30 min before imaging. Young adult animals were picked to agar plates with no bacterial lawn (30 worms per plate) and were transferred to second plate lacking bacteria after 5-10 min. Worm movement recordings were started 40-45 min after the worms were removed from food. Thirty second digital videos of individual animals were captured at 53 magnification and 4 Hz frame rate on a Zeiss Discovery Stereomicroscope using Axiovision software. The center of mass was recorded for each animal on each video frame using the object tracking in the Axiovision software. The trajectories were then analyzed using custom software written in Igor Pro 5.0 (Wavemetrics). For all comparisons to untreated wild-type controls, statistical significance was determined using the Tukey-Kramer test to control for multiple comparisons. For all pairwise comparisons of mutant and transgenic rescue strains, statistical significance was determined using a two-tailed Student's t test.
Fluorescence Imaging
All quantitative imaging was done using an Olympus PlanAPO 1003 1.4 NA objective and a CoolSNAP CCD camera (Hamamatsu). Worms were immobilized with 30 mg/ml BDM (Sigma). Image stacks were captured and maximum intensity projections were obtained using Metamorph 7.1 software (Molecular Devices). YFP fluorescence was normalized to the absolute mean fluorescence of 0.5 mm FluoSphere beads (Molecular Probes). For ventral or dorsal cord imaging, young adult worms, in which the ventral or dorsal cords were oriented toward the objective, were imaged in the region just posterior to the vulva. Imaging was done prior to aldicarb treatment and after 60 min of 1.5 mM aldicarb treatment. Line scans of ventral and dorsal cord fluorescence were analyzed in Igor Pro (WaveMetrics) using custom-written software to identify average peak fluorescence values for all puncta in the imaged region (peak punctal intensity) (Dittman and Kaplan, 2006) . For coelomocyte imaging, the posterior coelomocyte was imaged in larval stage 4 (L4) and early adult worms (Sieburth et al., 2007) . For all comparisons to untreated wild-type controls, statistical significance was determined using the Tukey-Kramer test to control for multiple comparisons. For all comparisons of control and aldicarb treated animals of the same genotype, statistical significance was determined using a two-tailed Student's t test.
Electrophysiology
Electrophysiology was done on dissected C. elegans as previously described (McEwen et al., 2006) . Worms were superfused in an extracellular solution containing 127 mM NaCl, 5 mM KCl, 26 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 20 mM glucose, 1 mM CaCl 2 , and 4 mM MgCl 2 , bubbled with 5% CO 2 , 95% O 2 at 20 C. Whole cell recordings were carried out at -60 mV using an internal solution containing 105 mM CH 3 O 3 SCs, 10 mM CsCl, 15 mM CsF, 4 mM MgCl 2 , 5 mM EGTA, 0.25 mM CaCl 2 , 10 mM HEPES, and 4 mM Na 2 ATP, adjusted to pH 7.2 using CsOH. Under these conditions, we only observed endogenous acetylcholine EPSCs. For endogenous GABA IPSC recordings the holding potential was 0 mV. All recording conditions were as described (McEwen et al., 2006) . Stimulus-evoked EPSCs were stimulated by placing a borosilicate pipette (5-10 mm) near the ventral nerve cord (one muscle distance from the recording pipette) and applying a 0.4 ms, 30 mA square pulse using a stimulus current generator (WPI). For aldicarb exposure, a single adult worm was transferred to a plate containing 1 mM aldicarb for 60 min prior to the dissection, with one exception, ckr-2 ACh rescue animals were treated for 30 min. For all comparisons to untreated wild-type controls, statistical significance was determined using the Tukey-Kramer test to control for multiple comparisons. For all comparisons of control and aldicarb-treated animals of the same genotype, statistical significance was determined using a two-tailed Student's t test.
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